Jci_page_head_homepage_01 Jci_page_head_homepage_02
Geraldine Siegfried, Ajoy Basak, James A. Cromlish, Suzanne Benjannet, Jadwiga Marcinkiewicz, Michel Chrétien, Nabil G. Seidah, Abdel-Majid Khatib
Published in Volume 111, Issue 11
J Clin Invest. 2003; 111(11):1723–1732 doi:10.1172/JCI17220
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4

Blockade of proVEGF-C processing. (a) Processing of proVEGF-C was analyzed by Western blotting in HEK 293 cells transiently cotransfected with the empty pIRES2-EGFP vector (None) and pcDNA3-zeo-Flag.cm5 vector containing proVEGF-C cDNA (Control), or with the pcDNA3-zeo-Flag.cm5 vector containing proVEGF-C and pIRES2-EGFP vector that expresses profurin, proPACE4, proPC5, and proPC7, wild-type or mutated α2-macroglobulin (α2-MG and α2-MG-F, respectively), and α1-antitrypsin. The corresponding percentages of proVEGF-C cleavage calculated from the ratio of band intensities of VEGF-C/(proVEGF-C + VEGF-C) is indicated. (b) CHO tumor cells were stably transfected with empty pcDNA3-zeo-Flag.cm5 vector (None), pcDNA3-zeo-Flag.cm5 vector containing wild-type proVEGF-C cDNA (HSIIRR227), or pcDNA3-zeo-Flag.cm5 vector containing mutated proVEGF-C cDNA (HSIISS227). Populations of stably transfected cells were selected using Zeocin resistance and analyzed by Western blot using the VEGF-C antibody.